Armesto M, Nemours S, Arestin M, Bernal I, Solano-Iturri J, Manrique M
Int J Mol Sci. 2024; 25(13).
PMID: 38999991
PMC: 11241516.
DOI: 10.3390/ijms25136881.
Yang M, Gong C, Song K, Huang N, Chen H, Gong H
Oxid Med Cell Longev. 2023; 2023:5885203.
PMID: 36846720
PMC: 9957629.
DOI: 10.1155/2023/5885203.
Alchahin A, Mei S, Tsea I, Hirz T, Kfoury Y, Dahl D
Nat Commun. 2022; 13(1):5747.
PMID: 36180422
PMC: 9525645.
DOI: 10.1038/s41467-022-33375-w.
Feng C, Lyu Y, Gong L, Wang J
Nutrients. 2022; 14(11).
PMID: 35684073
PMC: 9182762.
DOI: 10.3390/nu14112274.
Mier J
Curr Opin Oncol. 2019; 31(3):194-199.
PMID: 30985497
PMC: 6467495.
DOI: 10.1097/CCO.0000000000000512.
A comprehensive review of protein kinase inhibitors for cancer therapy.
Kannaiyan R, Mahadevan D
Expert Rev Anticancer Ther. 2018; 18(12):1249-1270.
PMID: 30259761
PMC: 6322661.
DOI: 10.1080/14737140.2018.1527688.
Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development.
Schueler J, Klingner K, Bug D, Zoeller C, Maier A, Dong M
Oncotarget. 2018; 9(57):30946-30961.
PMID: 30123419
PMC: 6089561.
DOI: 10.18632/oncotarget.25697.
Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma.
Noonan H, Metelo A, Kamei C, Peterson R, Drummond I, Iliopoulos O
Dis Model Mech. 2016; 9(8):873-84.
PMID: 27491085
PMC: 5007981.
DOI: 10.1242/dmm.024380.
Heritable Cancer Syndromes Related to the Hypoxia Pathway.
Henegan Jr J, Gomez C
Front Oncol. 2016; 6:68.
PMID: 27047799
PMC: 4801850.
DOI: 10.3389/fonc.2016.00068.
HIF2a inhibitors for the treatment of VHL disease.
Metelo A, Noonan H, Iliopoulos O
Oncotarget. 2015; 6(27):23036-7.
PMID: 26325097
PMC: 4695098.
DOI: 10.18632/oncotarget.4564.
Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model.
Metelo A, Noonan H, Li X, Jin Y, Baker R, Kamentsky L
J Clin Invest. 2015; 125(5):1987-97.
PMID: 25866969
PMC: 4463187.
DOI: 10.1172/JCI73665.
Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma.
Fu H, Liu Y, Xu L, Liu W, Fu Q, Liu H
Tumour Biol. 2015; 36(8):5791-9.
PMID: 25716202
DOI: 10.1007/s13277-015-3248-y.
Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.
Wang L, Williamson S, Wang M, Davidson D, Zhang S, Baldridge L
Mol Cancer. 2014; 13:39.
PMID: 24568263
PMC: 3945615.
DOI: 10.1186/1476-4598-13-39.
Increased expression of pregnancy up-regulated non-ubiquitous calmodulin kinase is associated with poor prognosis in clear cell renal cell carcinoma.
Wu S, Lv Z, Wang Y, Sun L, Jiang Z, Xu C
PLoS One. 2013; 8(4):e59936.
PMID: 23634203
PMC: 3636239.
DOI: 10.1371/journal.pone.0059936.
Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma.
Tousi F, Bones J, Iliopoulos O, Hancock W, Hincapie M
J Chromatogr A. 2012; 1256:121-8.
PMID: 22885037
PMC: 4392643.
DOI: 10.1016/j.chroma.2012.07.066.
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma.
Clark P
Biologics. 2010; 4:187-97.
PMID: 20714356
PMC: 2921256.
DOI: 10.2147/btt.s7818.
The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2.
Zimmer M, Lamb J, Ebert B, Lynch M, Neil C, Schmidt E
Cancer Res. 2010; 70(8):3071-9.
PMID: 20354189
PMC: 2861799.
DOI: 10.1158/0008-5472.CAN-09-2877.
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab.
Escudier B, Cosaert J, Jethwa S
Biologics. 2009; 2(3):517-30.
PMID: 19707382
PMC: 2721410.
DOI: 10.2147/btt.s3509.
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.
Clark P
Kidney Int. 2009; 76(9):939-45.
PMID: 19657325
PMC: 2963106.
DOI: 10.1038/ki.2009.296.
Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib.
Ivanyi P, Winkler T, Ganser A, Reuter C, Grunwald V
Dtsch Arztebl Int. 2009; 105(13):232-7.
PMID: 19629201
PMC: 2696772.
DOI: 10.3238/arztebl.2008.0232.